52 73

Cited 0 times in

Differences in Therapeutic Responses and Factors Affecting Post-Stroke Depression at a Later Stage According to Baseline Depression

Authors
 Eun-Jae Lee  ;  Jong S Kim  ;  Dae-Il Chang  ;  Jong-Ho Park  ;  Seong Hwan Ahn  ;  Jae-Kwan Cha  ;  Ji Hoe Heo  ;  Sung-Il Sohn  ;  Byung-Chul Lee  ;  Dong-Eog Kim  ;  Hahn Young Kim  ;  Seongheon Kim  ;  Do-Young Kwon  ;  Jei Kim  ;  Woo-Keun Seo  ;  Jun Lee  ;  Sang-Won Park  ;  Seong-Ho Koh  ;  Jin Young Kim  ;  Smi Choi-Kwon  ;  Min-Sun Kim  ;  Ji Sung Lee 
Citation
 Journal of Stroke, Vol.20(2) : 258-267, 2018 
Journal Title
 Journal of Stroke 
ISSN
 2287-6391 
Issue Date
2018
Keywords
Anger ; Depression ; Emotional incontinence ; Escitalopram ; Stroke
Abstract
BACKGROUND AND PURPOSE: The pathophysiology of post-stroke depression (PSD) is complex and may differ according to an individual's mood immediately after stroke. Here, we compared the therapeutic response and clinical characteristics of PSD at a later stage between patients with and without depression immediately after stroke. METHODS: This study involved a post hoc analysis of data from EMOTION (ClinicalTrials.gov NCT01278498), a placebo-controlled, double-blind trial that examined the efficacy of escitalopram (10 mg/day) on PSD and other emotional disturbances among 478 patients with acute stroke. Participants were classified into the Baseline-Blue (patients with baseline depression at the time of randomization, defined per the Montgomery-Asberg Depression Rating Scale [MADRS] >/=8) or the Baseline-Pink groups (patients without baseline depression). We compared the efficacy of escitalopram and predictors of 3-month PSD (MADRS >/=8) between these groups. RESULTS: There were 203 Baseline-Pink and 275 Baseline-Blue patients. The efficacy of escitalopram in reducing PSD risk was more pronounced in the Baseline-Pink than in the Baseline-Blue group (p for interaction=0.058). Several risk factors differentially affected PSD development based on the presence of baseline depression (p for interaction <0.10). Cognitive dysfunction was an independent predictor of PSD in the Baseline-Blue, but not in the Baseline-Pink group, whereas the non-use of escitalopram and being female were more strongly associated with PSD in the Baseline-Pink group. CONCLUSIONS: Responses to escitalopram and predictors of PSD 3 months following stroke differed based on the presence of baseline depression. Our data suggest that PSD pathophysiology is heterogeneous; therefore, different therapeutic strategies may be needed to prevent PSD emergence following stroke.
Files in This Item:
T201801775.pdf Download
DOI
10.5853/jos.2017.02712
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Neurology (신경과학교실) > 1. Journal Papers
Yonsei Authors
Heo, Ji Hoe(허지회) ORCID logo https://orcid.org/0000-0001-9898-3321
Export
RIS (EndNote)
XLS (Excel)
XML
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/162501
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse